As countries progress towards meeting UNAIDS 95-95-95 targets for HIV diagnosis, treatment and viral suppression, PEPFAR service implementers are approaching the “last mile” of identifying missing cases and new infections in the most hard-to-reach populations. MHRP’s PEPFAR implementing partners in Kenya’s South Rift Valley (SRV) led the country in identifying individuals living with HIV and getting them on treatment, according to 2023 4th quarter performance data.
MHRP is partnering with the Makerere University Walter Reed Project (MUWRP) in Uganda to conduct a novel HIV vaccine study called “RapidVax,” which recently started in March 2024. This study (RV591) combines experimental HIV vaccines with a novel dose escalation strategy with the goal of improving the body’s immune response.
MHRP, through an international collaboration, just launched a new study (RV584) in Tanzania to test novel long-acting bispecific antibody alone and in combination with another potent monoclonal antibody (mAb) to determine and compare safety and antiviral effects, or how effective these drugs are at reducing the amount of HIV in people living with HIV, both alone and in combination.
The African Cohort Study (AFRICOS) celebrated its 10th Anniversary on Wednesday 1st November, 2023, with a Research Symposium to review key findings from the study, share ongoing analyses, and discuss plans under the theme titled, “Progress and Future Directions.”
September 28, 2023, marked a significant milestone, as HJF Medical Research International Ltd/Gte. (HJFMRI Ltd/Gte.) celebrated the grand opening of its new office in Abuja, Nigeria. The new facility named, the Health Innovations Centre (HIC) is situated in the heart of the Federal Capital Territory (FCT).
